Congratulations to the Centre’s 2022 Honours students on their scholarship awards and we wish them all the best for their research and training
Validation of the Male Depression Risk Scale short form in a cross-sectional study of Australian men. Herreen D, Rice S, Zajac I. Brief assessment of male depression in clinical care:BMJ Open. 2022 Mar 28;12(3):e053650. doi: 10.1136/bmjopen-2021-053650.
Contact: Dr Ian Zajac
To celebrate International Women’s Day, the Centre is highlighting some of the fantastic women of men’s health that have been supported by the Centre and are achieving great work in the field. FCMHW encourages and commends the involvement of women in men’s health and hopes to further support it in the future.
Recovery of Male Reproductive Function After Ceasing Prolonged Testosterone Undecanoate Injections
Handelsman DJ, Desai R, Conway AJ, Shankara-Narayana N, Stuckey BG, Inder WJ, Grossmann M, Yeap BB, Jesudason D, Ly LP, Bracken K, Wittert GA. Eur J Endocrinol. 2022 Jan 1:EJE-21-0608.R2. doi: 10.1530/EJE-21-0608. Online ahead of print.PMID: 35000898
Contact: Gary Wittert
With progressed prostate cancer, men are no longer responding to the standard anti-androgen drug therapy. While developing new drugs often can take 15 years, this program will reduce this timeframe by aiming to re-purpose existing lipid-modifying medicines. We aim to take our laboratory findings into a proof-of-concept clinical trial to test whether trimetazidine is safe and effective in treating men on ADT, to prevent or delay the onset of lethal castrate resistant prostate cancer.
Through this trial we aim for a potential new therapeutic approach using existing drugs used to treat cardio-metabolic disease to prevent lethal prostate cancer, reduced drug-related toxicities in men being treated for prostate cancer, and Improved length and quality of life for men living with advanced prostate cancer.
Contact: Dr Zeyad Nassar
Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial.
Wittert G, Bracken K, Robledo KP, Grossmann M, Yeap BB, Handelsman DJ, Stuckey B, Conway A, Inder W, McLachlan R, Allan C, Jesudason D, Fui MNT, Hague W, Jenkins A, Daniel M, Gebski V, Keech A. Lancet Diabetes Endocrinol. 2021 Jan;9(1):32-45. doi: 10.1016/S2213-8587(20)30367-3.
Contact: Gary Wittert
In a prospective clinical trial across 5 Australian sites, we are giving men with prostate cancer statins (cholesterol lowering drug) to examine whether they reverse a poor prognosis lipidome signature.
ANZ Clinical Trials Register Study ID: ACTRN12617000965303 (NSW Study)
Contact: Professor Lisa Butler
A clinical trial of the cyclin dependent kinase inhibitor, ribociclib, is underway in collaboration with the Chris O’Brien Lifehouse in Sydney.
ANZCTR Study ID: ACTRN12618000354280
Contact: Professor Lisa Butler
